$3250 | Single User
$4650 | Site License
$5650 | Global License

Tuberculosis Drugs Market, By Therapy (First Line Therapy, Second Line Therapy, and Combination Therapy), By Disease Type (Active Tuberculosis, Latent Tuberculosis, and Drug-Resistant Tuberculosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026
[Lowest Price Guaranteed: $3,250]

Published by AnalystView: 01 Jun 2020 | 270630 | In Stock
Related Topics: Agencies , AstraZeneca , COVID , Drug , FDA , Food , Healthcare , Novartis , Pfizer , Pharmaceuticals , Pharmacy , Retail , Services

Introduction

REPORT HIGHLIGHT

The tuberculosis drugs market was valued at USD 1,045.8 million by 2019, growing with 5.2% CAGR during the forecast period, 2020-2026.

REPORT HIGHLIGHT

Tuberculosis or TB is a contagious bacterial infection (caused by bacteria called “Mycobacterium Tuberculosis”) that usually attacks the patient’s lungs. TB in general terms is a key health concern worldwide. In 2018, according to a report by the World Health Organization (WHO) around 10 million people were affected by tuberculosis. These cases were identified from all age groups. Thus, WHO identifies TB as the 9th leading cause of patient’s death. Tuberculosis disease is caused due to infection of Mycobacterium tuberculosis bacteria to the human lungs.

Market Dynamics

The rising number of patients suffering from tuberculosis coupled with favorable government support on spreading awareness regarding this disease is driving the industry growth. According to the World Health Organization (WHO) 2019 report, more than 10 million people are affected with tuberculosis condition every year, worldwide. The condition is a leading cause of death from a single infectious agent, accounting for one of the top 10 causes of death globally. Thus, the demand for TB therapeutics is set to increase over the forecast period, driving the market growth. Additionally, collaborations and assistance from international organizations including TB Alliance, WHO, and UNICEF to lower the burden caused due to the disease and addressing unmet medical needs, which is estimated to fuel market growth in the coming years. Also, the introduction of new anti-TB drug regimens, improvement in diagnostic tests in low-resource settings, such as drug susceptibility testing are some of the potential driving factors for the market growth. Furthermore, recommendations in favor of developing shorter regimens and the use of fourth-generation fluoroquinolones for MDR-TB are considered to be leading to changes in the TB drug market.

Despite such growth inducing factors, drug shortage especially in developing countries is estimated to create challenges for the growth of the market. Nonetheless, the introduction of a Multi-Drug Resistant Tuberculosis Program is likely to offer several opportunities for growth in the coming years. In addition, the high cost associated with the treatment of second-line TB will hamper the market growth. For example, as per the U.S. Department of Health & Human Services’ data, the average direct cost for the treatment of drug-susceptible TB would be around USD 16,000, USD 150,000 for MDR-TB, and USD 510,000 for the treatment of extensively drug-resistant TB (XDR-TB).

Therapy Takeaway

By therapy, tuberculosis drugs market is segmented into first-line (serve the Drug Susceptible or Sensitive (DS) TB patient), second-line (serve the Drug Resistant (DR) TB patient), and combination therapy. Among which, second-line TB therapy accounted for the highest revenue share as the cost of this therapy, particularly for Active TB is on the decline. The second line therapy is further segmented into injectable anti-tuberculosis drugs and fluoroquinolones. Some of the examples of the second-line category include moxifloxacin, levofloxacin, Bedaquiline, Linezolid, and Delamanid. Also, in 2019, Pretomanid is newly introduced second-line products, indicated for the treatment of drug-resistant TB.

On the other side, first-line therapy follows an upward growth with the developing countries are witnessing an increase in DS-TB incidence in both ATB and LTB forms. The segment is further segmented into rifampicin, ethambutol, isoniazid, pyrazinamide, and streptomycin.

Disease Type Takeaways

By disease type, the global tuberculosis drug industry is segmented into active tuberculosis, latent tuberculosis, and drug-resistant tuberculosis. Of these, the active tuberculosis segment held a substantial share owing to a rising number of active TB cases. According to the Centers for Disease Control and Prevention (CDC), more than 10 million people globally develop active TB on an annual basis. The ATB form involves symptomatic expression of Mycobacterium tuberculosis infection which is detected easily due to perceivable symptoms. On the contrary, latent tuberculosis is projected to grow with promising CAGR over the study period. The World Health Organization (WHO) defined latent TB as a state of the persistent immune response which is stimulated by M. tuberculosis antigens without clinically manifested active TB.

Distribution Channel Takeaways

Based on the distribution channel segment, the market is bifurcated into retail pharmacy, hospital pharmacy, and online pharmacy. Of these, the market is dominated by the hospital segment as the demand for medicines is increased due to a substantial rise in patients globally, particularly in the underdeveloped countries. Whereas, the online category is projected to grow with the fastest growth rate during the study period.

Regional Takeaway

Regionally, the overall market for tuberculosis drugs is divided into North America, Middle East & Africa, Asia Pacific, Latin America, and Europe. Of these, Asia Pacific dominated the market in the year 2019 owing to a higher prevalence of the disease in the region. According to the WHO, around one-third of the patients of the world are from the Asia Pacific region, which is creating a robust need for better treatment options.

Additionally, the Middle East & Africa region is estimated to witness the fastest growth of the market owing to an increase in patient pool coupled with the availability of treatments in the region. Furthermore, developed regions such as North America and Europe accounted for the significant revenue share. It is noted that the majority of the TB cases in these regions registered from foreign-born people who are entering these countries as well as those exposed to TB due to travel to regions.

COVID-19 Impact

The tuberculosis drug market is witnessing a few adverse effects due to the outbreak of COVID-19 globally. Patients are experiencing the unavailability of treatments and drugs due to lockdown in major areas of the world. Change in the role of hospitals treating tuberculosis is also a major concern, as there is an inevitable interruption in diagnostic, which creates risk for other house members, as they are more prone to the disease. The outbreak also results in lower enthusiasm among patients regarding regular check-ups and treatments. Such factors are witnessed to impact adversely from the past few months and may continue until the situation becomes normal regarding COVID.

Key Vendor Takeaway

The key players operating in the global tuberculosis drugs market include Pfizer, Inc., Novartis AG, Macleods Pharmaceuticals, Bayer AG, Cadila Healthcare, Lupin Limited, AstraZeneca plc, Johnson & Johnson, and Otsuka Pharmaceutical Co. Ltd.

These companies are looking for strategic mergers and acquisitions to expand their customer reach. Additionally, the companies are trying to enter into partnerships with several healthcare organizations for improving the drug and treatments. Further, the approvals of newer drugs and treatments by the US Food and Drug Administration (FDA) are majorly benefiting the players. For instance, in August 2019, the U.S. FDA approved a novel compound for highly drug-resistant forms of TB named “Pretomanid”. This molecule was developed by the non-profit TB Alliance and approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway).

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year – 2015 to2018

Base Year – 2019

Estimated Year – 2020

Projected Year – 2026

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Government and Regional Agencies

Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

TUBERCULOSIS DRUGS MARKET KEY PLAYERS

AstraZeneca plc

Johnson & Johnson

Bayer AG

Cadila Healthcare Ltd

Lupin Limited

Pfizer, Inc.

Novartis AG

Macleods Pharmaceuticals

Otsuka Pharmaceutical Co., Ltd.

Other players

TUBERCULOSIS DRUGS MARKET, BY THERAPY

First-Line Therapy

Isoniazid

Pyrazinamide

Rifampicin

Ethambutol

Streptomycin

Second-Line Therapy

Fluoroquinolones

Injectable Anti-tuberculosis Drugs

Combination Therapy

TUBERCULOSIS DRUGS MARKET, BY DISEASE TYPE

Latent Tuberculosis

Active Tuberculosis

Drug-Resistant Tuberculosis

TUBERCULOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

TUBERCULOSIS DRUGS MARKET, BY REGION

North America

The U.S.

Canada

Europe

Germany

France

Italy

Spain

United Kingdom

Rest of Europe

Asia Pacific

India

China

South Korea

Japan

Singapore

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

The Middle East and Africa

Saudi Arabia

United Arab Emirates

Rest of MEA

Table of Contents
for Tuberculosis Drugs Market, By Therapy (First Line Therapy, Second Line Therapy, and Combination Therapy), By Disease Type (Active Tuberculosis, Latent Tuberculosis, and Drug-Resistant Tuberculosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026

  • TABLE OF CONTENT

    1. TUBERCULOSIS DRUGS MARKET OVERVIEW

    1.1. Study Scope

    1.2. Assumption and Methodology

    2. EXECUTIVE SUMMARY

    2.1. Market Snippet

    2.1.1. Market Snippet by Therapy

    2.1.2. Market Snippet by Disease Type

    2.1.3. Market Snippet by Distribution Channel

    2.1.4. Market Snippet by Region

    2.2. Competitive Insights

    3. TUBERCULOSIS DRUGS KEY MARKET TRENDS

    3.1. Market Drivers

    3.1.1. Impact Analysis of Market Drivers

    3.2. Market Restraints

    3.2.1. Impact Analysis of Market Restraints

    3.3. Market Opportunities

    3.4. Market Future Trends

    4. TUBERCULOSIS DRUGS INDUSTRY STUDY

    4.1. Porter’s Five Forces Analysis

    4.2. Marketing Strategy Analysis

    4.3. Growth Prospect Mapping

    4.4. Regulatory Framework Analysis

    4.5. COVID-19 Impact Analysis

    4.5.1. Pre-COVID-19 Impact Analysis

    4.5.2. Post-COVID-19 Impact Analysis

    5. TUBERCULOSIS DRUGS MARKET LANDSCAPE

    5.1. Market Share Analysis

    5.2. Key Innovators

    5.3. Breakdown Data, by Key manufacturer

    5.3.1. Established Player Analysis

    5.3.2. Emerging Player Analysis

    6. TUBERCULOSIS DRUGS MARKET – BY THERAPY

    6.1. Overview

    6.1.1. Segment Share Analysis, By Therapy, 2019 & 2026 (%)

    6.2. First Line Therapy

    6.2.1. Overview

    6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    6.2.3. Rifampicin

    6.2.3.1. Overview

    6.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    6.2.4. Ethambutol

    6.2.4.1. Overview

    6.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    6.2.5. Isoniazid

    6.2.5.1. Overview

    6.2.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    6.2.6. Pyrazinamide

    6.2.6.1. Overview

    6.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    6.2.7. Streptomycin

    6.2.7.1. Overview

    6.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    6.3. Second Line Therapy

    6.3.1. Overview

    6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    6.3.3. Injectable Anti-Tuberculosis Drugs

    6.3.3.1. Overview

    6.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    6.3.4. Fluoroquinolones

    6.3.4.1. Overview

    6.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    6.4. Combination Therapy

    6.4.1. Overview

    6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    7. TUBERCULOSIS DRUGS MARKET – BY DISEASE TYPE

    7.1. Overview

    7.1.1. Segment Share Analysis, By Disease Type, 2019 & 2026 (%)

    7.2. Latent Tuberculosis

    7.2.1. Overview

    7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    7.3. Active Tuberculosis

    7.3.1. Overview

    7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    7.4. Drug-Resistant Tuberculosis

    7.4.1. Overview

    7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    8. TUBERCULOSIS DRUGS MARKET – BY DISTRIBUTION CHANNEL

    8.1. Overview

    8.1.1. Segment Share Analysis, By Distribution Channel, 2019 & 2026 (%)

    8.2. Hospital Pharmacy

    8.2.1. Overview

    8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    8.3. Retail Pharmacy

    8.3.1. Overview

    8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    8.4. Online Pharmacy

    8.4.1. Overview

    8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9. TUBERCULOSIS DRUGS MARKET– BY GEOGRAPHY

    9.1. Introduction

    9.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)

    9.2. North America

    9.2.1. Overview

    9.2.2. Key Manufacturers in North America

    9.2.3. North America Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)

    9.2.4. North America Market Size and Forecast, By Therapy, 2015 – 2026 (US$ Million)

    9.2.5. North America Market Size and Forecast, By Disease Types, 2015 – 2026 (US$ Million)

    9.2.6. North America Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)

    9.2.7. U.S.

    9.2.7.1. Overview

    9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.2.8. Canada

    9.2.8.1. Overview

    9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.3. Europe

    9.3.1. Overview

    9.3.2. Key Manufacturers in Europe

    9.3.3. Europe Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)

    9.3.4. Europe Market Size and Forecast, By Therapy, 2015 – 2026 (US$ Million)

    9.3.5. Europe Market Size and Forecast, By Disease Type, 2015 – 2026 (US$ Million)

    9.3.6. Europe Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)

    9.3.7. Germany

    9.3.7.1. Overview

    9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.3.8. Italy

    9.3.8.1. Overview

    9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.3.9. United Kingdom

    9.3.9.1. Overview

    9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.3.10. France

    9.3.10.1. Overview

    9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.3.11. Rest of Europe

    9.3.11.1. Overview

    9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.4. Asia Pacific (APAC)

    9.4.1. Overview

    9.4.2. Key Manufacturers in Asia Pacific

    9.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)

    9.4.4. Asia Pacific Market Size and Forecast, By Therapy, 2015 – 2026 (US$ Million)

    9.4.5. Asia Pacific Market Size and Forecast, By Disease Type, 2015 – 2026 (US$ Million)

    9.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)

    9.4.7. India

    9.4.7.1. Overview

    9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.4.8. China

    9.4.8.1. Overview

    9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.4.9. Japan

    9.4.9.1. Overview

    9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.4.10. South Korea

    9.4.10.1. Overview

    9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.4.11. Rest of APAC

    9.4.11.1. Overview

    9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.5. Latin America

    9.5.1. Overview

    9.5.2. Key Manufacturers in Latin America

    9.5.3. Latin America Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)

    9.5.4. Latin America Market Size and Forecast, By Therapy, 2015 – 2026 (US$ Million)

    9.5.5. Asia Pacific Market Size and Forecast, By Disease Type, 2015 – 2026 (US$ Million)

    9.5.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)

    9.5.7. Brazil

    9.5.7.1. Overview

    9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.5.8. Mexico

    9.5.8.1. Overview

    9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.5.9. Argentina

    9.5.9.1. Overview

    9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.5.10. Rest of LATAM

    9.5.10.1. Overview

    9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.6. Middle East and Africa

    9.6.1. Overview

    9.6.2. Key Manufacturers in Middle East and Africa

    9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 – 2026 (US$ Million)

    9.6.4. Middle East and Africa Market Size and Forecast, By Therapy, 2015 – 2026 (US$ Million)

    9.6.5. Middle East and Africa Market Size and Forecast, By Disease Type, 2015 – 2026 (US$ Million)

    9.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2015 – 2026 (US$ Million)

    9.6.7. Saudi Arabia

    9.6.7.1. Overview

    9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    9.6.8. United Arab Emirates

    9.6.8.1. Overview

    9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 – 2026, (US$ Million)

    10. KEY VENDOR ANALYSIS

    10.1. Cadila Healthcare Ltd

    10.1.1. Company Snapshot

    10.1.2. Financial Performance

    10.1.3. Product Benchmarking

    10.1.4. Strategic Initiatives

    10.2. Lupin Limited

    10.3. AstraZeneca plc

    10.4. Johnson & Johnson

    10.5. Bayer AG

    10.6. Pfizer, Inc.

    10.7. Novartis AG

    10.8. Macleods Pharmaceuticals

    10.9. Otsuka Pharmaceutical Co., Ltd.

    11. 360 DEGREE ANALYSTVIEW

    12. APPENDIX

    12.1. Research Methodology

    12.2. References

    12.3. Abbreviations

    12.4. Disclaimer

    12.5. Contact Us

List Of Tables
in Tuberculosis Drugs Market, By Therapy (First Line Therapy, Second Line Therapy, and Combination Therapy), By Disease Type (Active Tuberculosis, Latent Tuberculosis, and Drug-Resistant Tuberculosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026

List of Tables

TABLE List of data sources

TABLE Market drivers; Impact Analysis

TABLE Market restraints; Impact Analysis

TABLE tuberculosis drugs market: Therapy Snapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Therapy

TABLE Global tuberculosis drugs market, by Therapy 2015-2026 (USD Million)

TABLE Tuberculosis drugs market: Disease Type Snapshot (2018)

TABLE Segment Dashboard; Definition and Scope, by Disease Type

Table Global Tuberculosis Drugs Market, By Disease Type 2015-2026 (Usd Million)

Table Tuberculosis Drugs Market: Distribution Channel Snapshot (2018)

Table Segment Dashboard; Definition And Scope, By Distribution Channel

Table Global Tuberculosis Drugs Market, By Distribution Channel 2015-2026 (Usd Million)

Table Tuberculosis Drugs Market: Regional Snapshot (2018)

Table Segment Dashboard; Definition And Scope, By Region

Table Global Tuberculosis Drugs Market, By Region 2015-2026 (Usd Million)

Table North America Tuberculosis Drugs Market, By Country, 2015-2026 (Usd Million)

Table North America Tuberculosis Drugs Market, By Therapy, 2015-2026 (Usd Million)

Table North America Tuberculosis Drugs Market, By Disease Type, 2015-2026 (Usd Million)

Table North America Tuberculosis Drugs Market, By Distribution Channel, 2015-2026 (Usd Million)

Table Europe Tuberculosis Drugs Market, By Country, 2015-2026 (Usd Million)

Table Europe Tuberculosis Drugs Market, By Therapy, 2015-2026 (Usd Million)

Table Europe Tuberculosis Drugs Market, By Disease Type, 2015-2026 (Usd Million)

Table Europe Tuberculosis Drugs Market, By Distribution Channel, 2015-2026 (Usd Million)

FTable Asia Pacific Tuberculosis Drugs Market, By Country, 2015-2026 (Usd Million)

Table Asia Pacific Tuberculosis Drugs Market, By Therapy, 2015-2026 (Usd Million)

Table Asia Pacific Tuberculosis Drugs Market, By Distribution Channel, 2015-2026 (Usd Million)

Table Asia Pacific Tuberculosis Drugs Market, By Disease Type, 2015-2026 (Usd Million)

Table Latin America Tuberculosis Drugs Market, By Country, 2015-2026 (Usd Million)

Table Latin America Tuberculosis Drugs Market, By Distribution Channel, 2015-2026 (Usd Million)

Table Latin America Tuberculosis Drugs Market, By Therapy, 2015-2026 (Usd Million)

Table Latin America Tuberculosis Drugs Market, By Disease Type, 2015-2026 (Usd Million)

TABLE Middle East And Africa Tuberculosis Drugs Market, By Country, 2015-2026 (USD Million)

Table Middle East And Africa Tuberculosis Drugs Market, By Distribution Channel, 2015-2026 (Usd Million)

Table Middle East And Africa Tuberculosis Drugs Market, By Therapy, 2015-2026 (Usd Million)

Table Middle East And Africa Tuberculosis Drugs Market, By Disease Type, 2015-2026 (Usd Million)

List Of Figures, Charts and Diagrams
in Tuberculosis Drugs Market, By Therapy (First Line Therapy, Second Line Therapy, and Combination Therapy), By Disease Type (Active Tuberculosis, Latent Tuberculosis, and Drug-Resistant Tuberculosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026

List of Figures

FIGURE Tuberculosis Drugs market segmentation

FIGURE Market research methodology

FIGURE Value chain analysis

FIGURE Porter’s Five Forces Analysis

FIGURE Market Attractiveness Analysis

FIGURE COVID-19 Impact Analysis

FIGURE Pre & Post COVID-19 Impact Comparision Study

FIGURE Competitive Landscape; Key company market share analysis, 2018

FIGURE Therapy segment market share analysis, 2019 & 2026

FIGURE First Line Therapy segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Isoniazid market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Pyrazinamide market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Rifampicin market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Ethambutol market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Streptomycin market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Second Line Therapy segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Fluoroquinolones market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Injectable Antituberculosis Drugs market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Combination Therapy market size forecast and trend analysis, 2015 to 2026 (USD Million

FIGURE Disease Type segment market share analysis, 2019 & 2026

FIGURE Disease Type segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Latent Tuberculosis market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Active Tuberculosis market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Drug-Resistant Tuberculosis market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Distribution Channel segment market share analysis, 2019 & 2026

FIGURE Distribution Channel segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Hospital Pharmacy market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Retail Pharmacy market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Online Pharmacy market size forecast and trend analysis, 2015 to 2026 (USD Million)

FIGURE Regional segment market share analysis, 2019 & 2026

FIGURE Regional segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

Figure North America Tuberculosis Drugs Market Share And Leading Players, 2018

Figure Europe Tuberculosis Drugs Market Share And Leading Players, 2018

Figure Asia Pacific Tuberculosis Drugs Market Share And Leading Players, 2018

Figure Latin America Tuberculosis Drugs Market Share And Leading Players, 2018

Figure Middle East And Africa Tuberculosis Drugs Market Share And Leading Players, 2018

Figure North America Market Share Analysis By Country, 2018

Figure U.S. Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Canada Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Europe Tuberculosis Drugs Market Share Analysis By Country, 2018

Figure Germany Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (USD Million)

Figure Spain Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Italy Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Uk Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure France Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Rest Of The Europe Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Asia Pacific Tuberculosis Drugs Market Share Analysis By Country, 2018

Figure India Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure China Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Japan Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure South Korea Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Singapore Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Rest Of Apac Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Latin America Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Latin America Tuberculosis Drugs Market Share Analysis By Country, 2018

Figure Brazil Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

FIGURE Mexico Tuberculosis Drugs Market size, forecast and trend analysis, 2015 to 2026 (USD Million)

Figure Argentina Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Rest Of Latam Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Middle East And Africa Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Middle East And Africa Tuberculosis Drugs Market Share Analysis By Country, 2018

Figure Saudi Arabia Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure United Arab Emirates Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Additional Details

Publisher

AnalystView

Publisher Information

AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. Our company is led by a team of passionate, naturally curious, and strategic thinkers from different industry backgrounds.



These experts are dedicated to creating concrete market data analysis in various industries such as Healthcare, Bulk Chemicals, Semiconductors and Electronics, Foods and Beverages. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends.



We aim to be the number one choice for various clients who require credible data to make vital business decisions. We wish to be a trusted and reliable analytics partner to major business organizations.



We understand that critical business decisions can be taken only when verified, authentic information is available. Therefore, our experts work meticulously to provide our clients with the accurate data, so that they need not spend time in verifying it.



It is also our goal to help our clients ignore traditional research methods that require a large amount of capital, manpower, and most important of it all – the time. We know that these factors are precious to a company and always follow the latest research techniques that produce the required result in a short span of time.

Reference

270630 | AV640

Number of Pages

198

Report Format

PDF

AnalystView Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Tuberculosis Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Tuberculosis Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Pulmonary Tuberculosis Global Clinical Trials Review, H2, 2016
Pulmonary Tuberculosis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial rep...
31 Aug 2016 by Global Data USD $2,500 More Info
Pulmonary Tuberculosis Global Clinical Trials Review, H2, 2016
Pulmonary Tuberculosis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial rep...
31 Aug 2016 by Global Data USD $2,500 More Info
Respiratory Diseases: Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis--Supplier Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review
About this ReportThis new 366-page report from VPG Market Research presents detailed analysis of the...
28 Jun 2016 by Venture Planning Group (VPG) USD $9,850 More Info
France Respiratory Disease Market: Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis--Supplier Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review
About This ReportThis new 282-page report from VPG Market Research presents detailed analysis of the...
28 Jun 2016 by Venture Planning Group (VPG) USD $1,950 More Info
Germany Respiratory Disease Market: Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV, Tuberculosis--Supplier Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts, Technology Trends, Instrumentation Review
About This ReportThis new 283-page report from VPG Market Research presents detailed analysis of the...
28 Jun 2016 by Venture Planning Group (VPG) USD $1,950 More Info
Tuberculosis: US, Europe, Japan--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers
The report presents a detailed analysis of the Tuberculosis diagnostics market in the US, Europe (Fr...
24 Jun 2016 by Venture Planning Group (VPG) USD $4,350 More Info
Tuberculosis Global Clinical Trials Review, H1, 2016
Tuberculosis Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Tube...
29 Feb 2016 by Global Data USD $2,500 More Info
Mycobacterium Tuberculosis Infections Global Clinical Trials Review, H2, 2015
Mycobacterium Tuberculosis Infections Global Clinical Trials Review, H2, 2015SummaryGlobalData's cli...
30 Oct 2015 by Global Data USD $2,500 More Info

This report is published by AnalystView

AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. Our company is led by a team of passionate, naturally curious, and strategic thinkers from different industry backgrounds.

These experts are dedicated to creating concrete market data analysis in various industries such as Healthcare, Bulk Chemicals, Semiconductors and Electronics, Foods and Beverages. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends.

We aim to be the number one choice for various clients who require credible data to make vital business decisions. We wish to be a trusted and reliable analytics partner to major business organizations.

We understand that critical business decisions can be taken only when verified, authentic information is available. Therefore, our experts work meticulously to provide our clients with the accurate data, so that they need not spend time in verifying it.

It is also our goal to help our clients ignore traditional research methods that require a large amount of capital, manpower, and most important of it all – the time. We know that these factors are precious to a company and always follow the latest research techniques that produce the required result in a short span of time.

Download Free Report Summary PDF

Tuberculosis Drugs Market, By Therapy (First Line Therapy, Second Line Therapy, and Combination Therapy), By Disease Type (Active Tuberculosis, Latent Tuberculosis, and Drug-Resistant Tuberculosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Geography (EU, NA, APAC, LATAM, and MEA) – Analysis, Size, Share, Trends, & Forecast from 2020-2026 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...